Blaze Bioscience develops and commercializes products that assist surgeons to treat cancer patients.
Blaze Bioscience is a Seattle-based, privately-held biotechnology company dedicated to developing products that assist surgeons in their quest to improve the lives of cancer patients. Tumor Paint provides real-time, high-resolution intraoperative visualization of cancer cells, enabling better detection and more complete and precise surgical resection of cancer. The first Tumor Paint product candidate, which is a combination of a targeting peptide and a fluorescent beacon, is under development for multiple solid tumors. Blaze Bioscience was founded in 2010.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 12, 2017 | Series B | $16.10M | 3 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
B Cubed Ventures | — | Series B |
W&W Capital | — | Series B |
Keiretsu Forum | — | Series B |